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Background: In recent years, more and more evidence has demonstrated that a rare symptom, osteo-
necrosis of the jaw, may be associated with long-term use of bisphosphonates. Bisphosphonate-related
osteonecrosis of the jaw (BRONJ) adversely affects the quality of life, producing signiﬁcant morbidity in
afﬂicted patients. The most common signs and symptoms are swelling, exposed bone, local infection,
pathologic fracture of the jaw, etc.
Patients and methods: We report the case of an elderly female patient with alendronate-induced ONJ.
After the patient discontinued taking bisphosphonates and her physician prescribed antiseptic mouth-
washes and antibiotic drugs, her uncomfortable symptoms were relieved.
Results: This side effect rarely occurs in Taiwan; it causes permanent harm to patients. Moreover, it affects
the normal function of taking food. Therefore, this article includes a case report and a list of some related
papers systematically providing clinicians with a reference for future prescription of bisphosphonates.
Conclusion: Furthermore, we provide suggestions for the Mackay Memorial Hospital and dentists, in
anticipation of earlier measures being taken in order to avoid bisphosphonaterelated osteonecrosis, and
to reduce additional medical expenses resulting from this side effect.
Copyright  2012, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is
a recently reported disease. The ﬁrst cases of BRONJ associated with
the use of oral bisphosphonates were reported in 20031. Most of
the reported cases were patients who received intravenous
bisphosphonates. Only a few cases have been reported involving
patients with osteoporosis receiving low-dose oral bisphosphonate
therapy2. However, an increasing frequency of BRONJ has been
reported in patients who received oral bisphosphonates3. BRONJ
can remain asymptomatic for weeks or months and is recognized
only by the presence of exposed bone in the oral cavity, which is
sometimes painless2. Themost commonly reported initiating factor
for BRONJ development is tooth extraction, although periodontal
disease and denture trauma have been implicated. Given the
greater number of patients receiving oral bisphosphonates for the
treatment of osteoporosis, it is likely that most doctors may
encounter some patients with bisphosphonate-related osteonec-
rosis4. It is important to recognize the incidence of BRONJ in theral and Maxillofacial Surgery,
al Hospital #92, Section 2,
iwan Society of Geriatric Emergenpopulation and to assess the risk associated with long-term use,
more than 3 years, of oral bisphosphonates4. In this article, we
report the case of alendronate-induced BRONJ in an elderly female
in Taiwan.
2. Case report
An 83-year-old female visited our department of oral and
maxillofacial surgery in May 2008, with exposed bone over her
upper jaw for several weeks. According to her statement and an old
record, she had suffered from low back pain 5 years previously.
Osteoporosis was diagnosed after examination in our neurosurgery
department. A weekly drug containing alendronate 70 mg and
colecalciferol 2800 IU (Fosamax Plus) was prescribed and had
been taken by the patient since then. She reported improvement in
her symptoms and signs following the medication. However, she
felt a painful swelling over the left maxillary molar area, and visited
the oral and maxillofacial surgery department of another medical
center. BRONJ was suspected, and therefore the patient dis-
continued Fosamax Plus. Toothache persisted, however, and the
patient visited local dental clinics in March 2008, where the left
maxillary molars were extracted. Unfortunately, painful swellings
and discharge with a bad odor were noted after the tooth extrac-
tion. Following visits to local clinics, she was referred to our oralcy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Dental panoramic roentgenogram reveals the irregular bone destruction over the left maxilla.
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outpatient department (OPD), the patient was examined and
a 21 cm portion of necrotic maxillary alveolar bone was found to
be exposed. There were no signs of infection, including alveolar
osteitis, gingivitis/periodontitis and periapical pathologic ﬁndings
close to the lesion. Dental panoramic radiography (Fig. 1) and facial
bone computerized tomography (Fig. 2) revealed bony destruction
over the left maxillary bone causing maxillary sinus reactive
changes. According to the American Association of Oral and
Maxillofacial Surgeons (AAOMS) Position Paper on Bisphosphonate-
Related Osteonecrosis of the Jaws (Position Paper), the patient was
diagnosed with BRONJ. Conservative treatment included antiseptic
chlorhexidine mouthwashes and antibiotic drugs to relieve her
symptoms. A freed necrotic bone was removed 3 months after
conservative treatment under local anesthesia without any
complications. Pathological examination revealed sequestrumwith
bacteria colony. The wound healed uneventfully. No further bone
was exposed and no discharge was noted during the following 1.5
years.
3. Discussion
BRONJ is a devastating side effect of long-term bisphosphonates.
Oral bisphosphonates, which are used much more extensively than
intravenous bisphosphonates, are prescribed for the treatment of
bone resorption diseases, mainly osteopenia or osteoporosis5. Most
cases of BRONJ occur in patients who are receiving the newer-
generation nitrogen-containing bisphosphonates, including alendr-
onate sodium. The mechanism of action of nitrogen-containingFig. 2. Computerized tomographic scan reveals bony destruction over the left pbisphosphonates causing ONJ is starting to be recognized. These
nitrogen-containing bisphosphonates are analogues of pyrophos-
phate; they have a high afﬁnity to hydroxyapatite crystals and inhibit
bone resorption. They also inhibit osteoclast activity and thus
decrease bone remodeling2. Since the end of 2003, BRONJ has
become an increasing problem and evidence of this trend is the
increase in related case reports and a recently published case series6.
BRONJ risks were categorized as drug-related, local, and demo-
graphic or systemic factors7. Drug-related risk factors include
bisphosphonate potency and duration of therapy. Greater potency
and longer duration appear to be associated with increased risk8,9.
Furthermore, most cases of BRONJ are associatedwith long-term use
of bisphosphonates. Thus, a dose-dependent and time-dependent
relationship is thought to exist with respect to the disease process.
Therefore, the longer a person is taking alendronate, the greaterhis or
her risk of developing BRONJ3. Demographic factors, including age
and race, and cancer diagnosis, with or without osteoporosis, were
reported as risk factors for BRONJ7. Some studies reported increasing
age as consistently being associated with BRONJ10. Sex was not
statistically associated with BRONJ and race was reported to be a risk
factor, with Caucasians having an increased risk for BRONJ compared
with blacks11. Other related risk factors of BRONJ include intravenous
bisphosphonates, cancer, anti-cancer therapy, duration of exposure,
dental extractions, dental implants, poorly ﬁtting dentures, gluco-
corticoids, smoking, and preexisting dental disease. This case met
some of these conditions, including duration of exposure and dental
extractions. To distinguish BRONJ from other delayed healing
conditions, the following working deﬁnition of BRONJ was adopted
by the AAOMS in200912. Patientsmay be considered to have BRONJ ifosterior maxilla (A) and left maxillary reactive sinus polyps formation (B).
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treatment with a bisphosphonate; (2) exposed bone in the maxillo-
facial region that has persisted formore than eightweeks; and (3) no
historyof radiation therapy to the jaws. This casemet all of the above-
mentioned characteristics.
Here, we report a case of bone necrosis of the jaws in an Asian
patient treated with tablets containing alendronate 70 mg and
colecalciferol 2800 IU. According to the Naranjo causality assess-
ment scale4, the following four reasons describe why the case was
deﬁned as probably BRONJ: (1) much evidence has already been
published about BRONJ; (2) the patient developed the condition
following approximately 5e7 years of treatment with aldendro-
nate; (3) the possibility of other medications causing BRONJ could
be excluded because the patient took other medications simulta-
neously; and (4) her dentist made a diagnosis of BRONJ by pano-
ramic radiography and computerized tomography.
The Naranjo causality assessment scale score was 6 in this case,
which is deﬁned as a probable adverse drug reaction. In other
words, alendronate-induced BRONJ was identiﬁed in this case.
In Taiwan, one case was reported as BRONJ in 200713. There
were, however, several similar conditions. In this case, dental
extraction was performed without any precaution e this may be
the major cause of the BRONJ.
The conditions included the patient’s age, a causal relationship
of adverse drug reaction, and duration of bisphosphonate therapy.
Based on the concept of patient medication safety, it is important
for dentists to obtain and update all medical and medication
histories regularly, and dentists should exercise caution in planning
any dental procedures that may involve surgery, when patients are
receiving bisphosphonate treatment. These procedures include
periodontal surgical crown lengthening, periodontal osseous
surgery, extractions, and placement of dental implants and hard
tissue biopsies of the jawbones.
Recommendations for the prevention of BRONJ associated with
oral bisphosphonates according to the AAOMS Taskforce are as
follows12: (1) recent outcomes studies show improved outcome of
BRONJ treatment with drug cessation14,15; (2) patient education and
reassurance, control of pain, control of secondary infection, and
prevention of extension of lesion and development of new areas of
necrosis12; (3) it is recommended that patients be adequately
informed of the small risk of compromised bone healing. The utili-
zation of bone turnover marker levels in BRONJ, in conjunction with
a drug holiday, has been reported as an additional tool to guide
treatment decisions in patients exposed to oral bisphosphonates16;
and (4) surgical debridement has been variably effective in eradi-
cating the necrotic bone17,18. Patients with established BRONJ should
avoid elective dentoalveolar surgical procedures, since these surgical
sites may result in additional areas of exposed necrotic bone. The
effectiveness of hyperbaric oxygen therapy as an adjunct to non-
surgical and surgical treatment is under investigation at two insti-
tutions where a randomized, controlled trial is underway19.
Furthermore, we propose some suggestions for the Mackay
Memorial Hospital and dentists in anticipation of earlier measures
being taken in order to prevent BRONJ from occurring and to reduce
additional medical expenses resulting from this side effect. We
suggest that the Order Entry Systems of the Mackay Memorial
Hospital should build up and provide warnings about BRONJ. The
purpose of the Order Entry System is to remind our dentists that
the AAOMS suggests that, when performing dentoalveolar surgery
such as extractions and implants, patients who have taken oral
bisphosphonates for more than 3 years should discontinue treat-
ment for 3 months prior to performing the dental surgery and
restart when the bone has healed. Meanwhile, dentists should
educate patients about the importance of oral hygiene in order to
avoid BRONJ from occurring.In addition, the pharmacists should remind patients of one
major precaution prior to dentoalveolar surgery. The major
precaution is that they should actively quiz their dentist over taking
bisphosphonates.
4. Conclusion
In conclusion, an early diagnosis might prevent or reduce the
morbidity resulting from advanced destructive lesions of the jaw
bone. Meanwhile, long-term follow-up is necessary to care for
patients on bisphosphonate therapy and patients with proven
BRONJ.
Based on patient medication safety, all involved, including
dentists orthopedic surgeons, pharmacists, the pharmaceutical
company and the patients on bisphosphonate therapy, should be
aware of BRONJ.
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